@ind_org: “This is precision medicine in Parkinson's disease.” — Dr. Thomas Tropea What if a blood test could help researchers better understand who is at greater risk of developing dementia in Parkinson's disease? A new study led by Dr. Thomas Tropea offers a promising glimpse of how that might become possible. The study found that higher levels of a protein called P-tau217 in the blood were associated with a greater risk of cognitive decline in people with Parkinson's disease. These findings could help researchers identify people at higher risk and design more focused clinical trials, moving Parkinson's research toward approaches that account for individual differences. Research led by IND’s Dr. Thomas Tropea was recently highlighted by Dr. Connie Marras during the “Essential Highlights in Movement Disorders” session at the International Parkinson and Movement Disorder Society (MDS) Congress, bringing attention to its potential significance for the future of Parkinson's research. Read the study, published in Annals of Neurology: pubmed.ncbi.nlm.nih.gov/41848292
